MM-302 is a HER2-targeted antibody-PLD conjugate developed by Merrimack (MM) Pharmaceuticals and has been approved for clinical investigation in metastatic HER2-positive breast cancer. This evidence concerns the gene GPLD1 and breast carcinoma.